LIVER-DIRECTED SUPERPARAMAGNETIC IRON-OXIDE - QUANTITATION OF T(2) RELAXATION EFFECTS

被引：23

作者：

POULIQUEN, D

LUCET, I

CHOULY, C

PERDRISOT, R

LEJEUNE, JJ

JALLET, P

机构：

[1] Laboratoire de Biophysique, Faculte de Medecine

来源：

MAGNETIC RESONANCE IMAGING | 1993年 / 11卷 / 02期

关键词：

SUPERPARAMAGNETIC CONTRAST AGENTS; T(2); RELAXATION EFFECTS; LIVER;

D O I：

10.1016/0730-725X(93)90026-A

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

A new liver-directed superparamagnetic iron oxide nanoparticle preparation, MDL, is described. MDL is derived from previously developed MD particles only by modification of the characteristics of the coating: chemical structure and charge. The biodistribution, pharmacokinetics, and intratissular localization of both Fe-59-labeled MD and MDL particles were analyzed. R2 relaxivities determined in aqueous solution are compared to measurements in liver tissue and to R2 of nanoparticles incorporated into synthetic microcapsules, which represent a simplified cell pattern. T2 relaxation effects of both preparations in liver tissue are discussed relative to physical parameters such as iron oxide core dimension, total particle size, and charge, and pharmacological properties such as biodistribution, pharmacokinetics, and extra/intracellular localization.

引用

页码：219 / 228

页数：10

共 15 条

[1] Wolf, Burnet, Goldstein, Joseph, Contrast agents for magnetic resonance imaging, Magnetic Resonance Annual, pp. 231-266, (1985)
[2] Widder, Greif, Widder, Edelman, Brady, Magnetite albumin microspheres: A new MR contrast material, AJR, 148, pp. 399-404, (1987)
[3] Saini, Stark, Hahn, Wittenberg, Brady, Ferruci, Ferrite particles: A superparamagnetic MR contrast agent for the reticuloendothelial system, Radiology, 162, pp. 211-216, (1987)
[4] Weissleder, Stark, Engelstad, Bacon, Compton, White, Jacobs, Lewis, Superparamagnetic iron oxide: Pharmacokinetics and toxicity, AJR, 152, pp. 167-173, (1989)
[5] Pouliquen, Perdrisot, Ermias, Akoka, Jallet, Le Jeune, Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: Contribution of microencapsulation to improved biodistribution, Magn. Reson. Imaging, 7, pp. 619-627, (1989)
[6] Pouliquen, Le Jeune, Perdrisot, Ermias, Jallet, Iron oxide nanoparticles for use as an MRI contrast agent: Pharmacokinetics and metabolism, Magn. Reson. Imaging, 9, 3, pp. 275-283, (1991)
[7] Tomlinson, Theory and practice of site—specific drug delivery, Advanced Drug Delivery Reviews, 1, 2, (1987)
[8] Weissleder, Elizondo, Wittenberg, Rabito, Bengele, Josephson, Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MRI imaging, Radiology, 175, pp. 489-493, (1990)
[9] Illum, Davis, The targeting of drugs parenterally by use of microspheres, J. Parent. Sci. Tech., 36, pp. 242-248, (1982)
[10] Illum, Davis, The organ uptake of intravenously administered colloidal particles can be altered using a non ionic surfactant (poloxamer 338), Febs. Lett., 167, pp. 79-82, (1984)

← 1 2 →